9:15 am Chair’s Opening Remarks

Developing Next Generation Multispecifics for a Flourishing Future

9:20 am Uncovering the Therapeutic Potential of a Next Generation Tumor Treg Deplete


  • Uncovering INV322 as a next-generation bispecific Treg depleter that uses Invenra’s SNIPER B-Body® Technology
  • Capitalizing on avidity to deplete Tregs specifically in the tumor microenvironment by blocking both its targets and eliciting ADCC
  • Preclinical data supportive of INV322’s therapeutic potential will be shown. IND-enabling
    activities are underway

9:50 am Session Reserved for Gem Pharmatech


10:00 am Guided Antibody Tumor Engagers (TwoGATE™), a Sophisticated & Differentiated Approach for T Cell Redirection in Solid Tumors


  • Revolutionizing cancer treatment by harnessing the immune system. However, on-target off-tumor toxicities including Cytokine Release Syndrome limit their therapeutic potential
  • Developing TwoGATE™ is the split anti-CD3 paratope that enables a true dual Ag “AND” gate by targeting each inactive half-paratope to a different antigen on the same tumor cell for reassembly of the CD3 binding complex only on the tumor cell surface
  • Engineering, developability, in vitro and in vivo potency and NHP tolerability data as well as our thoughts on ways to overcome the barriers to successful T cell redirection in solid tumors will be discussed

10:30 am
Morning Break & Networking

Target Discovery, Mechanistic Diversity & Translational Science

Translational Science

11:00 am Translational PK/PD Investigations & Multiscale Mechanism-Based Modeling to Support Development of T Cell Redirecting Antibodies

  • Aman Singh Associate Director, Cell Therapy Clinical Pharmacology, Modeling & Bioinformatics, Takeda


  • Understanding unique features and prevailing challenges associated with I/O therapies
  • How mechanistic PK/PD model can help with the forward and reverse translation
  • Comprehending the utility of receptor occupancy and immune synapse in establishing a robust translational PK/ PD model for T-cell redirecting antibodies

11:30 am PreTarg-it®: A modular platform utilizing bispecific antibodies for optimized biodelivery of payloads.


  • Generating novel and highly potent bispecific antibody modalities to treat underserved patient populations living with solid cancers
  • Preclinical proof-of-concept has been achieved for oxMIF-specific pre-targeted radioimmunotherapy, using OncoOne’s proprietary PreTarg-it® platform.
  • This approach provides higher tumor to non-tumor ratios and improved therapeutic indexes than traditional approaches.

12:00 pm Session Reserved for Asimov


Novel Formats, Product Design & Manufacturability


11:00 am Session Reserved for Carterra


11:30 am Potency Assay Strategy from Early to Late Clinical Development: A Bispecifics Case Study

  • Azra Mujic-Delic Principal Scientist - Functional Characterization & Bioassays, Genmab


  • Defining appropriate release and stability approach for biological activity for IND filing
    • Correlation of surrogate potency assay to mechanism of action

12:00 pm Session Reserved for Applied BioMath


12:30 pm
Lunch & Networking

Solid Tumor Engagers

1:30 pm Decoupling Cytotoxicity with Cytokine Release: Development of Safe CD3 T Cell Engagers for Solid Tumors


  • Discovery and design of low affinity CD3 T cell engagers to set new standards for IO
  • Utilizing the affinity and avidity effect to selectively target FOLR1high ovarian cancer
  • Pre-clinical development of AMG-340, a PSMAxCD3 BiTE for mCRPC

2:00 pm Overcoming the Challenges of a First-Generation CD123-Directed Bispecific CD3-Engaging DART Molecule


  • Experience with the first-generation CD123 x CD3 DART molecule, flotetuzumab
  • Molecular engineering to uncouple cytolysis from cytokine release
  • Combinatorial approaches with standard-of-care agents

2:30 pm Generation of Innovative B7H4 x CD3 & B7H4 x 4-1BB Bispecifics for Solid Tumor Therapies

  • Musheng Bao Senior Director, Discovery Oncology, Harbour Biomed


  • Generation of innovative B7H4 x CD3 and B7H4 x 4-1BB bispecifics by using HBICE® bispecific platform
  • B7H4 x CD3 shows promising anti-tumor efficacy with limited cytokines release
  • B7H4 x 4-1BB further enhances B7H4 x CD3 efficacy, especially at low E:T ratio. It suggests combination of B7H4 x CD3 and B7H4 x 4-1BB therapy will provide new opportunities for solid tumor treatment

Data & AI

1:30 pm Graphical Design, Engineering & In Silico Cloning of Multispecific Antibodies


  • Designing and engineering proteins on a graphical user interface that also takes care of plasmid generation
  • Design and analyze molecules simultaneously
  • Turning protein design into a fun activity

2:00 pm TREAT 2.0: A Versatile Platform Technology for Development of Multispecific Antibodies

  • Ankita Srivastava Vice President - Protein Sciences & Rational Design, Ichnos Sciences


  • Unlocking new biology with TREAT 2.0 platform technology
  • Addressing the design and developability profiling by utilizing TREAT 2.0
  • Optimizing structure-activity relationships through epitope and affinity adjustments

2:30 pm Leveraging Homotypic Antibody Interfaces for Biotherapeutic Engineering

  • Brandon Leonard Principal Scientific Researcher - Antibody Engineering, Genentech


  • A homotypic interaction encoded by germline CDRL2 sequences enhances TNFRSF agonists
  • Engineering of a homotypic interface between heavy chain variable regions for heterodimeric receptor agonism
  • Novel antibody interfaces revealed through structural mining

3:00 pm
Afternoon Break & Networking

Multispecifics in Clinical Use & Combinational Mechanisms

3:30 pm Improving Bispecific Antibody Outcome in Acute Myeloid Leukemia


  • Bite and CAR T cell therapy is still in early phases of development compared to other diseases
  • Ideal target still to be found
  • Need to overcome immunosuppressive environment

4:00 pm Panel Discussion – Unlocking the Potential of Combinatorial Strategies of Bispecifics in a Clinical Setting

  • Prathap Shastri Scientific Director, DMPK, Preclinical Sciences and Translational Safety, Johnson & Johnson
  • Peter Ellmark Chief Scientific Officer, Alligator Bioscience


  • Specifically focusing on co-stimulation approaches and combinational efforts with other standards of care
  • Exploring the current, pre-clinical view and how this impacts early clinical trials

4:30 pm Chair’s Closing Remarks